Medical Treatment Utilization Schedule - drug formulary
The Division of Workers’ Compensation has adopted a drug formulary to implement Assembly Bill 1124 (Statutes 2015, Chapter 525). The regulations establish an evidence-based drug formulary, consistent with California’s Medical Treatment Utilization Schedule (MTUS), to augment the provision of high-quality medical care, maximize health, and promote return to work in a timely fashion, while reducing administrative burden and cost.
MTUS Drug Formulary – effective January 1, 2018
Healthcare providers treating, evaluating, or performing utilization review in the California workers’ compensation system may access the MTUS (ACOEM) Guidelines and MTUS Drug List at no cost by registering at https://www.mdguidelines.com/MTUS.
Pharmacy & Therapeutics Committee
The Administrative Director has appointed the P&T committee pursuant to Labor Code section 5307.29. The formulary regulations (title 8, Cal. Code Regs. §§9792.27.18 – 9792.27.23) set forth a description of the role of the Committee and the qualifications to serve.
DWC is Now Accepting Applications to serve on the Pharmacy & Therapeutics Committee for the 2023-2025 Term
Applications are currently being accepted to fill six positions on the committee, three physician positions (M.D. or D.O.) and three pharmacist positions. The Pharmacy & Therapeutics Committee advises the DWC Administrative Director on updates and improvements to the drug formulary which is part of the Medical Treatment Utilization Schedule. The Administrative Director appoints members of the committee pursuant to Labor Code section 5307.29. The committee meets quarterly (January, April, July, and October). Meetings are held in person at the Elihu Harris State Building in Oakland, California on the third Wednesday of the month from 12:30p.m.-2:30p.m. Members serve a two-year term. Committee members serve as volunteers without compensation, and are reimbursed for some travel expenses.
The formulary regulations (title 8, Cal. Code Regs. §§9792.27.18 – 9792.27.23) set forth a description of the role of the Committee and the qualifications to serve.
Please submit your application, conflict of interest disclosure form and any supporting documentation by Friday, May 12, 2023 to:
- Application for Appointment to the Pharmacy and Therapeutics Committee – Form DWC MTUS PT-APP
- Pharmacy and Therapeutics Committee Conflict of Interest Disclosure – Form DWC MTUS PT-COI
Questions about the application process can be emailed to email@example.com with the subject line “P&T Application Question.”
The DWC welcomes public comment on the MTUS Formulary and Drug List. Do you have suggestions regarding the exempt, non-exempt, special fill or peri-operative fill status of a medication? Injured workers, physicians, pharmacists, and others may submit their questions, comments, and suggestions to the DWC formulary email box at firstname.lastname@example.org.
- Modeling the Economic Impact of a California Workers' Compensation Formulary - RAND 2017
- Interim Status Report - April 2017
- Implementing a Drug Formulary for California’s Workers' Compensation Program – RAND, August 2016
- U.S. Food & Drug Administration Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations – Orange Book Publication and Orange Book Data Base
- MTUS Drug Formulary Webinar - December 13 and 14, 2017
The webinar provides an overview of the MTUS Drug Formulary regulations, including the adoption of the drug list, implementation of updated MTUS guidelines, a demo of the online formulary tools for pharmaceutical searches.
- Assembly Bill 1124
- Online physician education courses now available
DWC offers free online education courses providing continuing education credits for physicians, QMEs, chiropractors, and nurses. Current offerings include the use of the Medical Treatment Utilization Schedule (MTUS) and tips for Qualified Medical Evaluators (QME).
- DWC Invites Physicians and Pharmacists to Apply for Appointment to the Pharmacy & Therapeutics Committee for 2023-2025 Term
- DWC Pharmacy and Therapeutics Committee Meeting Scheduled for April 19